華康生物醫學(08622.HK)否認被交泰收購 稱與交泰及相關方沒有關係
格隆匯1月31日丨華康生物醫學(08622.HK)公佈,董事會留意到在中國內有若干媒體報道有關一家名叫交泰國際("交泰")的公司收購("該據稱收購")公司的謠言。董事會亦注意到近日有部分人士("該人士")到公司位於中國深圳市大鵬新區葵涌街道葵新社區銀葵路16號深圳君軒D棟一至三層的處所聲稱是交泰的苦主。
公司經向控股股東查詢並獲確認有關該據稱收購之謠言不真實並亳無根據。此外,於公吿日期,董事會謹此澄清及確認公司與(i)交泰及(ii)該人士的聲稱沒有關係。
公司保留一切權利對交泰及/或捏造及散佈有關集團的此類亳無根據的信息的人士採取適當行動。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.